Lee's Pharm Affiliate OK'd for Phase III Trial of PD-L1 for NSCLC

China Oncology Focus (COF), a Lee's Pharm affiliate, was approved to start a China Phase III trial of its anti-PD-L1 antibody as a first-line treatment for non-small cell lung cancer.  In 2014, COF in-licensed socazolimab from San Diego 's Sorrento Therapeutics. The China trial will be a multicenter, randomized, double blinded, parallel-group clinical combination test of socazolimab and chemotherapy. The Phase III approval was based on positive results from an earlier Phase Ib trial. More details.... Stock Symbols: (HK: 950) (NSDQ: SRNE) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.